KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as an Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) in Patients With Predominant Negative Symptoms.

Dragana Bugarski-Kirola, I-Yuan Liu, Celso Arango, Stephen R Marder

Schizophr Bull 52(1) sbaf034

PMID40181715
PMCIDPMC12809779
DOI10.1093/schbul/sbaf034
发表日期2025-04-04
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:非 KM 图。
摘要

摘要

BACKGROUND AND HYPOTHESES: Negative symptoms of schizophrenia (NSS) carry a substantial burden, and there are no treatments currently approved for NSS. The efficacy of pimavanserin, a selective 5-HT2A inverse agonist and antagonist, in treating NSS was assessed. STUDY DESIGN: ADVANCE-2 was a phase 3, randomized, double-blind, placebo-controlled study of pimavanserin in patients with schizophrenia and predominantly negative symptoms. Patients were randomized (1:1) to receive pimavanserin (34 mg/day) or placebo alongside ongoing background antipsychotic medication. Eligible adults were aged 18-55 years and had access to a caregiver. The primary and key secondary endpoints were the change from baseline to week 26 in the Negative Symptom Assessment-16 (NSA-16) total score and Clinical Global Impression-Schizophrenia Scale-Severity (CGI-SCH-S) negative symptom score, respectively. STUDY RESULTS: Of the 454 randomized patients, 71 (39 placebo; 32 pimavanserin) discontinued and 383 (188 placebo; 195 pimavanserin) completed the study. The safety and full analysis sets comprised 453 and 446 patients, respectively. The NSA-16 change from baseline to week 26 was not significantly different between groups (least squares mean difference: -0.67; SE, 0.95; [95% CI: -2.54, 1.20]; P = .48; Cohen's d effect size: 0.07). Treatment-emergent adverse events occurred in 30.4% with pimavanserin and 40.3% with placebo. CONCLUSIONS: In this study, pimavanserin was well tolerated, and although it demonstrated a similar treatment effect as in the prior phase 2 study favoring pimavanserin, treatment with pimavanserin vs placebo did not result in significant differences for primary or other endpoints.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Patient disposition (safety analysis set).
非 KM Figure
Figure 2.Least squares mean (+/− SE) change in the NSA-16 Total Score from Baseline-by-Study Visit (Full Analysis Set). LSM, least squares mean; MMRM, mixed-effect model for repeated measures; NSA-16, 16-item Negative Symptom Assessment, negative symptom assessment; SE, standard error. LSM from MMRM with fixed effects of region (Europe or the rest of the world), planned treatment (adjunctive pimavanserin, adjunctive placebo), study visit (weeks 2, 4, 8, 14, 20, 26), treatment-by-visit interaction, baseline score (continuous covariate), and baseline-by-visit interaction.
非 KM Figure